Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

7.090 +0.560 (+8.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 591,959
Open 6.580
Bid (Size) 6.800 (1)
Ask (Size) 7.110 (1)
Prev. Close 6.530
Today's Range 6.530 - 7.150
52wk Range 3.140 - 13.70
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga

Performance

YTD
-1.66%
-1.66%
1 Month
-13.11%
-13.11%
3 Month
-10.37%
-10.37%
6 Month
-5.47%
-5.47%
1 Year
+101.99%
+101.99%

More News

Read More
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 4/12
Via Investor Brand Network
Fulcrum Therapeutics Inc. (NASDAQ: FULC) is a Stock Spotlight on 3/6
Via Investor Brand Network
FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Participate in Upcoming May Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.